Price Momentum and Market Performance
Venus Remedies closed at ₹777.00 on 29 Jan 2026, marking a 3.57% increase from the previous close of ₹750.20. The stock traded within a range of ₹740.30 to ₹778.00 during the day, inching closer to its 52-week high of ₹848.90. This price action reflects renewed investor confidence and a positive shift in momentum.
Comparatively, the stock has outperformed the Sensex across multiple timeframes. Over the past week, Venus Remedies surged 5.57%, significantly ahead of the Sensex’s 0.53% gain. Year-to-date, the stock has appreciated 1.30%, while the Sensex declined 3.37%. Over one year, Venus Remedies delivered a remarkable 185.45% return, dwarfing the Sensex’s 8.49% rise. Even on a longer horizon, the stock’s 10-year return of 583.98% far exceeds the Sensex’s 236.52%, underscoring its strong growth trajectory within the Pharmaceuticals & Biotechnology sector.
Technical Indicator Analysis: MACD and RSI
The Moving Average Convergence Divergence (MACD) indicator is signalling bullish momentum on both weekly and monthly charts. The weekly MACD line has crossed above its signal line, confirming short-term upward momentum, while the monthly MACD remains firmly bullish, indicating sustained strength over a longer horizon.
Conversely, the Relative Strength Index (RSI) presents a mixed picture. The weekly RSI currently shows no definitive signal, hovering in a neutral zone that suggests neither overbought nor oversold conditions. However, the monthly RSI is bearish, indicating some caution as the stock may be approaching overextended levels on a longer-term basis. This divergence between weekly and monthly RSI readings suggests that while short-term momentum is positive, investors should monitor for potential corrections or consolidation phases.
Moving Averages and Bollinger Bands
Daily moving averages reinforce the bullish narrative, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment typically signals a strong uptrend and supports the recent upgrade in technical trend from mildly bullish to bullish.
Bollinger Bands on the weekly chart are also bullish, with the price nearing the upper band, indicating strong buying pressure. On the monthly timeframe, the bands are mildly bullish, suggesting moderate volatility and a steady upward trend without excessive price spikes.
Additional Technical Signals: KST, Dow Theory, and OBV
The Know Sure Thing (KST) oscillator confirms bullish momentum on both weekly and monthly charts, adding further weight to the positive outlook. However, Dow Theory presents a more nuanced view: weekly signals are mildly bearish, reflecting some short-term caution, while the monthly trend shows no clear direction. This mixed signal advises investors to remain vigilant for potential trend shifts.
On-Balance Volume (OBV) analysis reveals mild bearishness on the weekly chart, indicating that volume trends have not fully confirmed the price gains recently. The monthly OBV shows no distinct trend, suggesting volume patterns are currently neutral. This volume behaviour warrants monitoring, as sustained price increases ideally should be supported by rising volume to confirm strength.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Mojo Score Upgrade and Market Capitalisation
Venus Remedies’ Mojo Score has improved to 80.0, reflecting a Strong Buy rating as of 28 Jan 2026, upgraded from a previous Buy grade. This upgrade is supported by the positive technical momentum and robust fundamentals. The company holds a Market Cap Grade of 4, indicating a sizeable market capitalisation that supports liquidity and investor interest.
The upgrade in Mojo Grade is a significant endorsement from MarketsMOJO’s proprietary scoring system, which integrates technical, fundamental, and sentiment data to provide a comprehensive investment rating. This Strong Buy rating aligns with the bullish technical signals and the company’s impressive historical returns.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies benefits from favourable industry tailwinds including increased healthcare spending, innovation in drug development, and rising demand for pharmaceutical products. The sector’s resilience during market volatility further supports the stock’s positive outlook.
Within this context, Venus Remedies’ technical strength and market performance position it as a compelling candidate for investors seeking exposure to growth in healthcare innovation and biotechnology advancements.
Curious about Venus Remedies Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Investment Considerations and Outlook
While the technical indicators predominantly signal bullish momentum, investors should be mindful of the mixed signals from the monthly RSI and Dow Theory, which suggest potential short-term volatility or consolidation. The mild bearishness in weekly OBV also calls for caution, as volume confirmation is crucial for sustaining upward trends.
Nonetheless, the strong performance relative to the Sensex, the upgrade to Strong Buy, and the alignment of multiple technical indicators such as MACD, moving averages, and KST oscillator provide a compelling case for continued strength in Venus Remedies’ share price.
Given the company’s leadership in the Pharmaceuticals & Biotechnology sector and its impressive long-term returns, Venus Remedies remains an attractive option for investors with a medium to long-term horizon seeking growth exposure in healthcare innovation.
In summary, the recent technical parameter changes reflect a clear shift in price momentum towards a bullish trend, supported by robust market performance and a favourable sector backdrop. Investors should monitor volume trends and RSI signals for any signs of short-term correction but can generally view the stock’s outlook as positive.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
